Intron a, Introna(interferon alfa-2b)
Intron A, IntronA, Viraferon (interferon alfa-2b) is a protein pharmaceutical. Interferon alfa-2b was first approved as Intron a on . It is used to treat BCR-ABL positive chronic myelogenous leukemia, brain neoplasms, chronic hepatitis b, chronic hepatitis c, and colorectal neoplasms amongst others in the USA. It has been approved in Europe to treat BCR-ABL positive chronic myelogenous leukemia, carcinoid tumor, chronic hepatitis b, chronic hepatitis c, and follicular lymphoma amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 2 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon alfa-2b
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Intron A | interferon alfa-2b | Merck Sharp & Dohme | N-103132 DISCN | 14 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| intron a | Biologic Licensing Application | 2023-03-07 |
Indications
FDA
EMA
Show 21 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
interferon alfa-2b, Intron A, Merck Sharp & Dohme LLC | |||
| 2095-11-21 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0148 | Injection, pegylated interferon alfa-2b, 10 mcg |
Clinical
Clinical Trials
451 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 6 | 24 | 39 | 19 | 34 | 115 |
| Hepatitis c | D006526 | — | B19.2 | 9 | 13 | 15 | 7 | 23 | 60 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 7 | 8 | 5 | 2 | 4 | 24 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 3 | 4 | 9 | 5 | 5 | 24 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 8 | 1 | — | 9 |
| Lymphoma | D008223 | — | C85.9 | — | 3 | 2 | 1 | 1 | 7 |
| Hepacivirus | D016174 | — | — | — | 1 | 1 | 3 | 2 | 6 |
| Hepatitis b | D006509 | — | — | — | — | 2 | 1 | 2 | 5 |
| Fibrosis | D005355 | — | — | — | 1 | 1 | 1 | — | 3 |
| Hiv | D006678 | — | O98.7 | 1 | 1 | — | 1 | — | 3 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 20 | 27 | 15 | — | 4 | 62 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | 8 | 2 | — | — | 11 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 6 | 4 | — | — | 10 |
| Polycythemia vera | D011087 | — | D45 | 1 | 3 | 5 | — | — | 8 |
| Multiple myeloma | D009101 | — | C90.0 | — | 4 | 4 | — | — | 7 |
| Chronic hepatitis | D006521 | — | K73.9 | 3 | 2 | 1 | — | — | 5 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 2 | 1 | — | 2 | 5 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | 2 | — | 1 | 5 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 3 | 2 | — | — | 4 |
| Essential thrombocythemia | D013920 | — | D47.3 | — | 2 | 1 | — | — | 3 |
Show 23 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 10 | 4 | — | — | — | 13 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 12 | — | — | — | 13 |
| Leukemia | D007938 | — | C95 | 2 | 5 | — | — | 1 | 7 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 2 | — | — | 1 | 5 |
| Colorectal neoplasms | D015179 | — | — | 2 | 3 | — | — | 1 | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 3 | — | — | — | 4 |
| Urinary bladder neoplasms | D001749 | — | C67 | 2 | 1 | — | — | 1 | 4 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | — | 3 | — | — | 1 | 4 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | 1 | — | — | 2 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 3 | — | — | — | 3 |
Show 36 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intravenous substance abuse | D015819 | — | — | — | — | — | — | 1 | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Cone dystrophy | D000077765 | — | — | — | — | — | — | 1 | 1 |
| Cone-rod dystrophies | D000071700 | — | — | — | — | — | — | 1 | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 1 | 1 |
| Angioedema | D000799 | EFO_0005532 | T78.3 | — | — | — | — | 1 | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | — | — | 1 | 1 |
| Hydrops fetalis | D015160 | HP_0001789 | P56.0 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Interferon alfa-2b |
| INN | — |
| Description | Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980. It was developed at Biogen, and ultimately marketed by Schering-Plough under the trade name Intron-A. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon® Alfa R.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201558 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00105 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,516 documents
View more details
Safety
Black-box Warning
Black-box warning for: Intron a
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,830 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use